Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer. (PubMed, JAMA Netw Open) - Oct 16, 2026 - "Lutetium Lu 177 vipivotide tetraxetan (Lu-177) prostate-specific membrane antigen (PSMA) is a targeted radioligand therapy approved for patients with metastatic androgen pathway modulator-resistant (mAPMR) prostate cancer after progression on androgen receptor pathway inhibitors (ARPIs)...In this cohort study, outcomes with Lu-177 PSMA were broadly consistent across treatment lines and taxane sequencing groups. These findings may help inform patient counseling, although prospective studies are needed to determine the optimal treatment sequencing strategy."
Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|
|
Edwin Lin; Georges Gebrael; Haoran Li; Krishnam Goel; Laxmi Upadhyay; Micah Ostrowski; Neeraj Agarwal; Nicolas Sayegh; Rachel Revillo; Tejita Agarwal; Umang Swami; Varun Nandakumar; Vinay Mathew Thomas; Yeonjung Jo; Zeynep Irem Ozay
|